公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2023 | HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy | Yu, Helena A; Goto, Yasushi; Hayashi, Hidetoshi; Felip, Enriqueta; CHIH-HSIN YANG ; Reck, Martin; Yoh, Kiyotaka; Lee, Se-Hoon; Paz-Ares, Luis; Besse, Benjamin; Bironzo, Paolo; Kim, Dong-Wan; Johnson, Melissa L; Wu, Yi-Long; John, Thomas; Kao, Steven; Kozuki, Toshiyuki; Massarelli, Erminia; Patel, Jyoti; Smit, Egbert; Reckamp, Karen L; Dong, Qian; Shrestha, Pomy; Fan, Pang-Dian; Patel, Parul; Sporchia, Andrea; Sternberg, David W; Sellami, Dalila; Jänne, Pasi A | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 14 | 5 | |
2023 | Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301 | Cho, Byoung Chul; Ahn, Myung-Ju; Kang, Jin Hyoung; Soo, Ross A; Reungwetwattana, Thanyanan; CHIH-HSIN YANG ; Cicin, Irfan; Kim, Dong-Wan; Wu, Yi-Long; Lu, Shun; Lee, Ki Hyeong; Pang, Yong-Kek; Zimina, Anastasia; Fong, Chin Heng; Poddubskaya, Elena; Sezer, Ahmet; How, Soon Hin; Danchaivijitr, Pongwut; Kim, YuKyung; Lim, Yeji; An, Taewon; Lee, Hana; Byun, Hae Mi; Zaric, Bojan | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 15 | 1 | |
2022 | LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer | Tsuboi, Masahiro; Goldman, Jonathan W; Wu, Yi-Long; Johnson, Melissa L; Paz-Ares, Luis; CHIH-HSIN YANG ; Besse, Benjamin; Su, Weiji; Chao, Bo H; Drilon, Alexander | Future oncology (London, England) | 9 | 7 | |
2023 | Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies | Popat, Sanjay; Ahn, Myung-Ju; Ekman, Simon; Leighl, Natasha B; Ramalingam, Suresh S; Reungwetwattana, Thanyanan; Siva, Shankar; Tsuboi, Masahiro; Wu, Yi-Long; CHIH-HSIN YANG | Targeted oncology | 5 | 5 | |
2023 | Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis | Liam, Chong Kin; Ahmad, Azura Rozila; Hsia, Te-Chun; Zhou, Jianying; Kim, Dong-Wan; Soo, Ross Andrew; Cheng, Ying; Lu, Shun; Shin, Sang Won; CHIH-HSIN YANG ; Zhang, Yiping; Zhao, Jun; Berghoff, Karin; Bruns, Rolf; Johne, Andreas; Wu, Yi-Long | Clinical cancer research : an official journal of the American Association for Cancer Research | 8 | 4 | |
2023 | Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial | Mazieres, Julien; Paik, Paul K; Garassino, Marina C; Le, Xiuning; Sakai, Hiroshi; Veillon, Remi; Smit, Egbert F; Cortot, Alexis B; Raskin, Jo; Viteri, Santiago; Wu, Yi-Long; CHIH-HSIN YANG ; Ahn, Myung-Ju; Ma, Rui; Zhao, Jun; O'Brate, Aurora; Berghoff, Karin; Bruns, Rolf; Otto, Gordon; Johne, Andreas; Felip, Enriqueta; Thomas, Michael | JAMA oncology | 11 | 4 | |
2015 | The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials. | Lee, Chee; Davies, Lucy Claire; Wu, Yi-Long; Mitsudomi, Tetsuya; Inoue, Akira; Rosell, Rafael; Zhou, Caicun; Nakagawa, Kazuhiko; Throngprasert, Sumitra; Fukuoka, Masahiro; Gralla, Richard J.; Gebski, Val; Mok, Tony; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |